Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 68Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 56Neoplasm Metastasis 55Breast Neoplasms 50Multiple Myeloma 42Colorectal Neoplasms 40Pancreatic Neoplasms 33Carcinoma, Renal Cell 32Myelodysplastic Syndromes 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 25Glioblastoma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Urinary Bladder Neoplasms 22Lymphoma 22Burkitt Lymphoma 21Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Hepatocellular 19Glioma 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Specimen Handling × 1 year × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡